Munich, July 3rd, 2024
stradoo® is excited having published a new though leadership piece on Big Data and AI in Life Sciences.
The publication authored by Polina Zayakina and Dr. Michael C. Müller has been ac-cepted for the 06/2024 issue of the renowned pharmind magazine. In this paper the authors explored how the key players are revolutionizing the Life Sciences sector us-ing Big Data and AI.
Transforming Life Sciences with Date-driven Innovation – delves into the pioneering initiatives of key players in the field, spotlighting their contributions and capabilities. In the rapidly evolving landscape of life sciences and healthcare, the integration of Big Data platforms is heralding a revolutionary era of research and patient care.
Beginning with a comprehensive exploration of the definition and characteristics of Big Data within the context of life sciences, the article elucidates the manifold bene-fits of leveraging these platforms. In-depth profiles of prominent companies such as Flatiron Health, Owkin, Tempus and multiple others reveal the scope of their services. These companies are leveraging artificial intelligence (AI), real-world evidence (RWE), and genomic data to develop predictive models, refine treatments and ena-ble personalized care. The challenges of data quality, privacy, interoperability, and regulatory compliance are examined alongside potential solutions, including stand-ardization and harmonized frameworks.
For any further questions, please do not hesitate to contact stradoo at any time and muenchen@stradoo.com.
Munich, January 14th, 2024
Severe obesity in childhood can halve life expectancy, stradoo® modelling study finds
-
- Impact of age of onset, severity and duration of childhood obesity quantified for the first time
- Early onset obesity model finds that a child who is living with severe obesity at age 4 and doesn’t lose weight has life expectancy of just 39. But weight loss can give back decades of life.
- Childhood obesity is a life-threatening disease, say researchers
stradoo® developed an innovative model on severe obesity in childhood based on age of obesity onset, obesity duration, irreversible risk accumulation (a measure of irreversible risks of obesity – health effects that remain even after weight loss) and se-verity of obesity.
The new research being presented at the European Congress on Obesity (ECO) in Venice, Italy (12-15 May) has, for the first time, quantified the impact of different as-pects of childhood obesity on long-term health and life expectancy.
The presentation has received global attention throughout the medical and lay press ***Press Clipping***.
The modelling by stradoo®, a globally acting life sciences consultancy in Munich, Germany, initiated and supported by Rhythm Pharmaceuticals and presented by Jan Luca Schorfheide and Dr. Urs Wiedemann, of stradoo, as well as colleagues at universities and hospitals in the UK, Netherlands, France, Sweden, Spain, USA and Germany found that age of onset, severity and duration of obesity all take their toll on life expectancy.
The development of obesity at a very young age was found to have a particularly profound effect.
For example, a child living with severe obesity (BMI Z-score of 3.5) at the age of four, who doesn’t subsequently lose weight, has a life expectancy of 39 years– about half of the average life expectancy.
Dr. Wiedemann says: “While it’s widely accepted that childhood obesity increases the risk of cardiovascular disease and related conditions such as type 2 diabetes (T2D), and that it can reduce life expectancy, evidence on the size of the impact is patchy.”
“A better understanding of the precise magnitude of the long-term consequences and the factors that drive them could help inform prevention policies and ap-proaches to treatment, as well as improve health and lengthen life.”
To learn more, stradoo® created an early onset obesity model that allowed them to estimate the effect of childhood obesity on cardiovascular disease and related con-ditions such as type 2 diabetes (TD2), as well as life expectancy.
Data came from 50 existing clinical studies on obesity and obesity-related comorbidi-ties, such as type 2 diabetes, cardiovascular events and fatty liver. The studies in-cluded more than 10 million participants from countries around the world, approx. 2.7 million of whom were aged between 2 and 29 years.
Dr Wiedemann says: “The early onset obesity model shows that weight reduction has a striking effect on life expectancy and comorbidity risk, especially when weight is lost early in life. The impact of childhood obesity on life expectancy is profound.”
“It is clear that childhood obesity should be considered a life-threatening disease. It is vital that treatment isn’t put off until the development of type 2 diabetes, high blood pressure or other ‘warning signs’ but starts early. Early diagnosis should and can im-prove quality and length of life.”
For any further questions, please do not hesitate to contact stradoo at any time and muenchen@stradoo.com.
Munich, January 10th, 2024
stradoo® FROM STRUGGLE TO SURGE – Pharmaceutical Markets in Africa on the Rise
Countries north and south of the Sahara are taking significant steps in healthcare in-frastructure and regulatory reforms. Driven by population growth, urbanization, and economic development, the pharmaceutical market in Africa continues to increase significantly.
In stradoo®’s latest publication “FROM STRUGGLE TO SURGE”, we explore this compel-ling and rapidly evolving landscape of the emerging markets in Africa.
The shift towards local production, changing disease profiles, and plenty of interna-tional health initiatives present unique opportunities for pharmaceutical companies to foster their own growth.
FROM STRUGGLE TO SURGE provides a comprehensive exploration of the African phar-maceutical market, its business opportunities, and future prospects. Our investigation delves into the interplay between historical precedents, current trends, and future tra-jectories.
stradoo® – a renowned strategy consulting firm specializing in life sciences – is known for custom made strategy development in international markets, utilizing proprietary methodologies and Big-Data driven tools. We serve our clients globally in launching products and in defining and rolling-out innovative going to market models.
We hope you will enjoy reading this publication and remain at your disposal under muenchen@stradoo.com.
Munich, November 1st, 2022
stradoo is excited about supporting the OPTIMA consortium improving patient outcomes and making healthcare systems more efficient.
Optimal treatment for patients with solid tumors in Europe through Artificial Intelligence (in short: OPTIMA) is a collaborative European oncology research project funded by the Innovative Medicines Initiative (IMI), a public-private partnership between the European Union, represented by the European Commission, and the European Federation of Pharmaceutical Industries and Associations (EFPIA).
stradoo – a globally acting strategy consulting and advisory firm focusing exclusively on the Life Science industry – is currently supporting the IMI initiative with a project to build a “Sustainability Strategy for OPTIMA” and to identify potential pathways and business models for the time after the grant period. stradoo has already collected comparable experience in previous IMI projects and has successfully supported PIONEER and HARMONY as well as other RWE projects and scientific partners (various patient registries, etc.) in the past.
Munich, June 1st, 2021
stradoo® has been honored with the prestigious Pharma Tech Outlook Award “Top 10 Pharma Marketing Consultancy”. As a life sciences focused strategy consulting firm headquartered in Germany and operating globally, stradoo has been commended with this award and holds this title with great pride and honor.
Pharma Tech Outlook is a leading monthly publication that has been a pioneer in bringing forth key trends in the pharmaceuticals industry, real world solutions, and the implications for pharma marketing. The magazine is based on a unique learn-from-peers approach providing decision markers a platform to constantly sharing their experience, wisdom and thought leadership among each other.
Annually, Pharma Tech Outlook compiles a list of “the most commendable pharmaceutical marketing consultancies” based on the recommendations of a distinguished panel of prominent CEOs, CIOs, VCs, analysts, and the editorial board of Pharma Tech Outlook. Following an evaluation, the resulting list comprises “10 companies that are at the forefront of providing Pharma Marketing consulting services and transforming businesses” in Europe.
stradoo® has been recognized for this award due to its distinguishing core principles of providing consulting services to its clients in the pharmaceutical and life sciences industry: combining deep industry knowledge and expertise with historically proven innovative project methodologies, stradoo fosters long-term success and operational excellence with its clients.
Alongside years of experience and high customer satisfaction, this reward supports stradoo’s success as a uniquely positioned consultancy in the pharmaceutical and life sciences industry.
Munich, September 12th, 2018
GHO Capital, the European specialist investor in healthcare, has recently completed the acquisition of Linimed Gruppe, a leading provider of outpatient intensive care services across Germany, from Vitruvian Partners.
stradoo® supported GHO Capital as commercial and strategic advisor on the transaction. On the back of deep industry experience and a wide range network in the care industry stradoo was able to provide GHO Capital with valuable insights into the company and the transaction.
Headquartered in Jena, Linimed Gruppe is one of the largest providers of outpatient intensive care in Germany, operating through 44 clinical care locations. The Com-pany is the leading provider of outpatient intensive care in community settings, enabling efficient care to the highest quality standards. The core service offering of Lin-imed consists of 24/7 intensive care in specialised community centres to patients with severe health problems (including neurological and neuromuscular diseases, ob-structive respiratory diseases, restrictive thoracic diseases, premature birth, as well as other conditions).
The Company has approximately 1,100 employees and operates a portfolio of modern and functional facilities positioned mostly in Eastern and Central Germany. The high quality of Linimed facilities, coupled with high standards of care, has contrib-uted to the attainment of best-in-class quality ratings.
The outpatient intensive care market in Germany currently consists of approximately 20,000 patients. Over the past five years, community care has risen from 12% to 31% of outpatient intensive care provision. Over the next five years, the overall number of patients is expected to increase to 26,000 with community care growing at an esti-mated compound annual growth rate of 16%.
Alan MacKay, Executive Partner & Founder of GHO Capital, commented: “At GHO we look to partner with the best healthcare businesses in Europe – working with stradoo® gave GHO valuable insights for the Linimed Gruppe transaction such that we were able to confirm our preliminary assessment of Linimed Gruppe as best in class.”
Munich, November 1st, 2017
stradoo®, – a newly founded strategy firm and M&A advisory – has announced its inauguration in 2017.
